| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Interim Results example | INB-100 Acute Myeloid Leukemia (AML) | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | |
Interim Results example | INB-100 Acute Myeloid Leukemia (AML) | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | |
Interim Results example | INB-100 Acute Myeloid Leukemia (AML) | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
IN8bio, Inc.$1.42
0 (0%)
D 24Pipeline Score Richly Valued Biotech · Clinical
Market Cap
16.44 M
EPS
-2.85
P/E Ratio
-
Value Trade
148.88 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
2.61 M
Operating CF
-4.95 M
Total Assets
26.27 M
Total Liabilities
3.48 M
Equity
22.78 M
D/E Ratio
12,345
5.7 %
Week
7.74 %
1 Month
2.45 %
3 Month
3.09 %
6 Month
-99.44 %
5 Year
-99.44 %
All Time
Cash Data
Cash Position
21.94 M
Monthly Burn
1.65 M
Runway
11.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
18.94 K
52 Week Range
1.17 - 5.61
% held by Insiders
14.05 %
% held by Institutions
37.5 %
Enterprise Value
-3.14 M
Total Shares
9.84 M
Short %
0.66 %
Float Shares
6.96 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IN8bio, Inc.
408Total events
6Upcoming
39Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 6
TBD
T2FDA Feedback Received
Discussions with FDA on potential clinical pathways including accelerated approval
Event history 402
Jun 3, 2026
●PublicationPresentation
Publication in Nature Communications: Harnessing γδ T cells through engineering and combination therapies
Jun 1, 2026
▲Oral PresentationPresentation
Updated overall survival data presented at ASCO 2026
newly diagnosed glioblastomasource ↗
Jun 1, 2026
◆Poster PresentationINB-200Presentation
Poster at ASCO 2026: INB-200 Phase I study in newly diagnosed GBM
Glioblastoma multiforme (GBM)source ↗
May 21, 2026
May 14, 2026
◆Oral PresentationPresentation
Presented translational data at ISCT 2026 and ASGCT 2026
glioblastomasource ↗
May 14, 2026
◆Oral PresentationPresentation
Oral presentation at ASGCT 2026: Challenging the Glioblastoma Status Quo: Could γδ T Cells Shift the Balance?
Glioblastomasource ↗
May 7, 2026
◆Poster PresentationPresentation
Poster at ISCT 2026: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma
Glioblastomasource ↗
Mar 12, 2026
Mar 2, 2026
Feb 12, 2026
◆Oral PresentationPresentation
IO360° Conference: IN8bio’s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM
glioblastomasource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 23%
Micro Cap (rank 699 of 906)
Percentile RankIN8bio, Inc. faces pipeline headwinds (24/100), with $30M risk-adjusted pipeline value, led by EAGD T-cell infusion in Acute Myeloid Leukemia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EAGD T-cell infusion Small molecule | Acute Myeloid Leukemia | Phase 1 | NCT03533816 | 5% | $30M | RECRUITING | 38 | - | - | Jan 1, 2028 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DeltEx DRI | newly diagnosed glioblastoma | Phase 1/2 | 2026-06-01 | median overall survival: exceeding 19.5 months; median progression free survival: 13.0 months; survival rate 24 months: 43%; standard of care survival rate 24 months: 20%; standard of care median overall survival: 13.2 months; standard of care median progression free survival: 6.6 months Read More | IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 Read More | |
DeltEx DRI | newly diagnosed glioblastoma | Phase 1/2 | 2026-06-01 | median overall survival: exceeding 19.5 months; median progression free survival: 13.0 months; survival rate 24 months: 43%; standard of care survival rate 24 months: 20%; standard of care median overall survival: 13.2 months; standard of care median progression free survival: 6.6 months Read More | IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 Read More | |
DeltEx DRI | newly diagnosed glioblastoma | Phase 1/2 | 2026-06-01 | median overall survival: exceeding 19.5 months; median progression free survival: 13.0 months; survival rate 24 months: 43%; standard of care survival rate 24 months: 20%; standard of care median overall survival: 13.2 months; standard of care median progression free survival: 6.6 months Read More | IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INABIN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio, a clinical-stage biopharmaceutical company, has announced the publication of a review article in Nature Communications, focusing on advancements in gamma-delta T cell engineering and combination therapies for cancer. The publication, authored by leading oncologists, outlines innovative strategies that could enhance anti-tumor efficacy, especially in solid tumors. In particular, the unique properties of gamma-delta T cells and their potential to improve immunotherapy approaches are underscored.
Read more →INABIN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
IN8bio presented updated clinical data for its DeltEx DRI at the ASCO 2026 conference, showing a median overall survival exceeding 19.5 months and a median progression-free survival of 13.0 months among patients with newly diagnosed glioblastoma. This data indicates a significant advancement over the standard-of-care, which has not changed in over 20 years. The therapy was well tolerated with no notable adverse effects, suggesting a positive outlook for patients facing this aggressive cancer. These findings underscore the potential of gamma-delta T cell therapy in transforming glioblastoma treatment outcomes.
Read more →INABIN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
IN8bio has presented new translational data highlighting the effectiveness of its DeltEx Drug Resistant Immunotherapy (DRI) in glioblastoma at major scientific forums. The findings suggest that repeated dosing of genetically modified gamma-delta T cells can preserve immune function and improve survival outcomes in patients. Data indicates a significant increase in intratumoral CD8+ T cell density, alongside reduced immune exhaustion markers, supporting the therapy's potential in reshaping the tumor microenvironment. The research lays the groundwork for future biomarker discovery and treatment optimization.
Read more →INABIN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio reported its financial results for Q1 2026, highlighting advancements in its gamma-delta T cell therapies. The company has shown promising data for glioblastoma treatments and plans to engage with the FDA regarding regulatory pathways. Upcoming milestones include presentations at major conferences and further updates at their R&D Day in May.
Read more →INABIN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio, a clinical-stage biopharmaceutical company, is set to present new clinical data and showcase its gamma-delta T cell programs at several upcoming medical conferences. Notably, they will hold an R&D Day on May 21, 2026, where they will highlight their novel T cell engager platform and its applications for cancer therapy. Key presentations will also occur at the ASCO Annual Meeting, focusing on the clinical progress of their gamma-delta T cell therapies for glioblastoma and other indications.
Read more →INABIN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio, Inc. announced the grant of nonqualified stock options for two new employees, amounting to 11,800 shares. This grant, made under Nasdaq Listing Rule 5635(c)(4), aims to bolster the company's team as they continue to develop their γδ T cell therapies. The stock options will vest over four years, emphasizing ongoing employment. IN8bio's focus remains on addressing unmet medical needs with their unique product candidates targeting cancer and autoimmune diseases.
Read more →INABIN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio reported its financial results for Q4 and full-year 2025, highlighting advancements in its gamma-delta T cell therapy programs, particularly for glioblastoma. The company announced a $40.2 million private placement to strengthen its financial position. Updated clinical data showed improved survival outcomes for patients treated with their therapies, indicating progress despite the aggressive nature of the disease.
Read more →INABIN8bio to Present at TD Cowen 46th Annual Health Care Conference
IN8bio, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO William Ho will discuss the company's recent achievements and upcoming milestones. The conference will also feature one-on-one investor meetings and will take place in Boston from March 2-4, 2026.
Read more →INABIN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer. Dr. Rochlin, who has been with the company since 2020, will oversee operations as IN8bio advances its clinical pipeline. She has played a key role in developing the company's T cell engager platform and has extensive experience in biotechnology. Her promotion is expected to strengthen the organization further.
Read more →INABIN8bio to Present at Upcoming Investor and Scientific Conferences in February
IN8bio, Inc. announced its participation in two upcoming conferences in February 2026. CEO William Ho will present at the Noble Emerging Growth Virtual Equity Conference and the IO360° Conference, where he will discuss the company's unique DeltEx Drug Resistant Immunotherapy approach and results from a Phase 1/2 study in glioblastoma. Additional details will be available on their website.
Read more →INABIN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
IN8bio, Inc. has reported updated clinical data from its INB-200 and INB-400 trials for newly diagnosed glioblastoma, highlighting significant survival improvements with its DeltEx Drug-Resistant Immunotherapy gamma-delta T cells. The median progression-free survival has doubled compared to the standard-of-care, with many patients remaining progression-free for several years. Overall survival rates continue to improve, and treatment is well-tolerated with no severe adverse events. These results showcase the potential of DeltEx DRI to enhance outcomes for glioblastoma patients.
Read more →INABIN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
IN8bio has announced a private placement to raise up to $40.2 million, with an initial closing of $20.1 million. The funds will support the development of INB-619, a novel gamma-delta T cell engager, and extend the company's financial runway into 2027. The financing includes participation from various institutional investors and aims to facilitate IND enabling studies and FDA interactions.
Read more →INABIN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
IN8bio, Inc. reported its financial results for Q3 2025, highlighting significant advancements in its gamma-delta T cell therapies. The company presented promising preclinical data on INB-619 and expanded its INB-100 clinical trial to multiple sites. CEO William Ho emphasized the potential of their DeltEx platform and the goal of redefining immune modulation for better patient outcomes.
Read more →INABIN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio has expanded its Phase 1 clinical trial of INB-100 by adding The Ohio State University as a new site. This addition aims to accelerate patient enrollment and reflects strong interest in the therapy. The trial evaluates the safety and effectiveness of INB-100 in patients undergoing haploidentical stem cell transplantation, with promising early results in long-term remissions.
Read more →INABIN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio presented promising preclinical data on INB-619, a gamma-delta T cell engager, at the ACR Convergence Meeting. The data showed complete B cell depletion with minimal adverse cytokine release, suggesting a superior safety profile compared to existing therapies. INB-619's unique mechanism could enable deeper immune modulation in autoimmune diseases, highlighting its potential as a first-in-class treatment.
Read more →INABIN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights • Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in p
IN8bio reported its financial results for Q2 2025, showcasing significant advancements in its clinical trials and product development. The company highlighted an extended median progression-free survival of 16.1 months for GBM patients treated with INB-200, along with a remarkable four-year milestone without disease progression for one patient. Additionally, IN8bio's DeltEx manufacturing platform received the Host Region USA East Abstract Award. Financially, the company reported a reduced net loss compared to the previous year, reflecting strategic changes in R&D expenditures.
Read more →INABIN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
IN8bio announced that Patient 009 in the Phase 1 trial of INB-200 for glioblastoma has achieved a significant milestone by remaining in remission for four years. This outcome surpasses typical progression-free survival rates observed in other trials. The treatment has shown promising results, including a favorable safety profile and extended survival compared to standard therapies. IN8bio continues to advance its innovative gamma-delta T cell therapies for cancer.
Read more →INABIN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio announced positive Phase 1 trial results for INB-200 in newly diagnosed glioblastoma multiforme (GBM). The trial showed that half of the patients remained progression-free for over 18 months, significantly surpassing historical benchmarks. The treatment was well-tolerated with no serious adverse effects reported, highlighting its potential as a novel immunotherapy for GBM.
Read more →INABIN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
IN8bio presented promising preclinical data for INB-619, a T cell engager targeting CD-19, at the 2025 ASGCT Annual Meeting. The data indicates that INB-619 can eliminate pathogenic B cells in patients with Systemic Lupus Erythematosus while expanding gamma-delta T cell levels. This approach may offer a safer alternative to conventional therapies for autoimmune diseases.
Read more →INABIN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
IN8bio presented new data on its gamma-delta T cell manufacturing at ISCT 2025, highlighting the effectiveness and consistency of its DeltEx™ Allo process. The presentation earned the Host Region Abstract Award, showcasing the company's commitment to producing robust cellular therapies. Key findings from the INB-100 trial indicate long-term remissions in AML patients, with ongoing enrollment at the recommended Phase 2 dose.
Read more →INABIN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights • Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leuke
IN8bio has released its financial results for the first quarter of 2025, highlighting significant advancements in their gamma-delta T cell therapies. Clinical data for INB-100 shows a remarkable 100% relapse-free rate in treated Acute Myeloid Leukemia patients over a median follow-up period of 20.1 months. Additionally, the company presented new developments regarding INB-600, a next-generation therapy, at major oncological meetings. Despite positive clinical data, IN8bio reported a net loss of $5.6 million for the quarter, raising concerns regarding its financial stability and operational costs.
Read more →INABIN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
IN8bio, a clinical-stage biopharmaceutical company, will present new clinical and preclinical data from its gamma-delta T cell therapies at several upcoming scientific conferences. The presentations will highlight the company's innovative approaches in oncology and autoimmune diseases, showcasing their capabilities in manufacturing and the clinical potential of their therapies. Key conferences include AACR, ISCT, ASGCT, and ASCO.
Read more →INABIN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 First gamma-delta ( ) TCE to demonstrate significant T cell expansion and activation, potentially offering an
IN8bio, a clinical-stage biopharmaceutical company, has announced promising preclinical data from its next-generation gamma-delta T cell engager (TCE) platform, which will be presented at the AACR 2025. The platform demonstrated significant cancer-targeting capabilities while minimizing harmful side effects associated with conventional TCE approaches. The data suggests that IN8bio's TCE platform can effectively target cancer cells in leukemia models, with potential applications in other challenging cancer types and autoimmune diseases. This innovative technology may provide a scalable and flexible solution for developing future T cell therapies.
Read more →INABIN8bio to Participate at the 11th Annual Immuno-Oncology 360 Conference 2025
IN8bio, a clinical-stage biopharmaceutical company, will participate in the Immuno-Oncology 360° Conference 2025 from March 24-26 in Boston. The CEO, William Ho, will co-chair the conference and discuss critical topics related to immunotherapy for autoimmune diseases. He is expected to present on the implications of a gamma-delta T cell engager in therapy development, reinforcing IN8bio's focus on innovative cancer treatments. This participation underscores the company's commitment to advancing immuno-oncology solutions.
Read more →INABIN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights • Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat c
IN8bio reported its fourth quarter and full-year 2024 financial results, highlighting advancements in its gamma-delta T cell therapies. The company noted continued success in ongoing Phase 1 and Phase 2 clinical trials, particularly with the INB-100 program for AML, which demonstrated a remarkable 100% relapse-free rate. Additionally, IN8bio introduced a new gamma-delta T cell engager platform, INB-600, targeted at treating various cancers and autoimmune diseases. However, the company faced a significant net loss and has paused enrollment in its Phase 2 glioblastoma program to optimize resources.
Read more →INABIN8bio Announces Advanced Gamma-Delta ( ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases Proprietary platform represents the first known approach capable of sustained T cell expansion, eliminating tar
IN8bio unveiled its novel gamma-delta T cell Engager (TCE) platform, INB-600, aimed at enhancing T cell expansion for oncology and autoimmune disease treatments. The first candidate, INB-619, targets CD19, showing promise in preclinical models for deep B cell depletion without the need for lymphodepletion. This platform may lead to improved safety and tolerability while actively expanding the immune response. The company is looking to conduct further preclinical studies and explore partnerships for future trials.
Read more →INABIN8bio to Present at the TD Cowen 45th Annual Health Care Conference
IN8bio, Inc., a clinical-stage biopharmaceutical company, announced that its CEO, William Ho, will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025. The company specializes in gamma-delta T cell therapies aimed at treating cancer. Their lead program, INB-400, is currently in a Phase 2 trial for glioblastoma (GBM), while other programs are in Phase 1 trials targeting various solid and hematologic tumors. This event highlights IN8bio's ongoing efforts to advance their innovative immunotherapy approaches.
Read more →INABIN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
IN8bio, Inc. will have its CEO, William Ho, present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025. The company specializes in gamma-delta T cell therapies and is actively advancing its clinical programs, including INB-400 in a Phase 2 trial for glioblastoma. The presentation is expected to enhance the company's exposure in the biopharmaceutical sector and further engage potential investors.
Read more →INABIN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio presented promising Phase 1 data for its gamma-delta T cell therapy, INB-100, at the 2025 TCT Meetings, highlighting its effectiveness in preventing relapses in high-risk acute myeloid leukemia (AML) patients. The results showed no relapses after a median follow-up of over 20 months, with a 1-year progression-free survival rate of 90.9% and a remarkable overall survival rate of 100%. Additionally, the therapy demonstrated a favorable safety profile with no treatment-related deaths or severe adverse effects. This innovation may offer a significant improvement in post-transplant treatment options for AML.
Read more →INABIN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients 100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with
IN8bio announced positive results from their Phase 1 trial of INB-100, an innovative gamma-delta T cell therapy for leukemia patients. 100% of the treated AML patients remain in complete remission after nearly two years post-transplant, surpassing typical outcomes for this high-risk group. The therapy shows promise in improving long-term survival while preserving patients' quality of life. Additionally, INB-100 appears to have minimal side effects compared to other cell therapies, positioning it as a potentially transformative treatment option in the leukemia space.
Read more →INABIN8bio to Present at Biotech Showcase 2025 in San Francisco
IN8bio, Inc. will have its CEO, William Ho, participate in the upcoming Biotech Showcase 2025, scheduled for January 13-15. The company aims to present its innovative gamma-delta T cell therapies for cancer during this event. Additionally, IN8bio management will be available for meetings with investors in San Francisco during the 43rd Annual J.P. Morgan Health Care Conference. Their lead program, INB-100, focuses on adopting specialized T cell therapies to improve outcomes for cancer patients.
Read more →INABIN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting INB-100 continu
IN8bio reported promising results from its Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for older AML patients, at the 2024 ASH Annual Meeting. As of September 30, 2024, all ten patients treated remained alive and progression-free, with a median complete response duration of 16.4 months. The study highlighted the therapy's ability to provide durable remissions and a favorable safety profile, with no instances of cytokine release syndrome or neurotoxicity. INB-100 has shown potential for in vivo expansion and persistence, suggesting continued protection against leukemic relapse.
Read more →INABIN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio, Inc. will have its CEO, William Ho, present at the Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on December 3, 2024. The presentation will cover the company's innovative gamma-delta T cell therapies aimed at treating cancer. Key details of the event will be available through a webcast, which will be accessible for 90 days post-event. IN8bio's lead program, INB-400, is currently undergoing a Phase 2 trial for glioblastoma multiforme, indicating active progress in their therapeutic development.
Read more →INABIN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting 50% of patients who received repeated doses (n=10) remained aliv
IN8bio presented results from its fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. The results indicate a significant advancement in the treatment of glioblastoma with 50% of patients on repeated doses remaining alive. The therapy showed a 79% increase in median progression-free survival when compared with the standard treatment regimen. INB-200, combined with standard therapies, demonstrated positive treatment effects and a favorable safety profile, indicating potential for it to be a first-in-class therapy.
Read more →INABIN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hemat
IN8bio, Inc. announced its third-quarter 2024 financial results, highlighting that all patients treated with INB-100 for Acute Myeloid Leukemia are in complete remission. The company obtained FDA guidance for the advancement of INB-100 towards a potential registrational trial while planning to expand enrollment in the ongoing Phase 1 study. Additionally, IN8bio closed a private placement securing $11.6 million to extend its cash runway through early 2026. However, the company suspended its Phase 2 trial for INB-400 and reported significant severance charges related to workforce reductions.
Read more →INABIN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio, Inc. announced a plenary oral presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 21-24, 2024. The presentation will detail long-term follow-up data from the Phase 1 trial of INB-200, an autologous gamma-delta T cell therapy for newly diagnosed glioblastoma. Preliminary results showed that 92% of treated patients surpassed the standard median progression-free survival of 7 months. The results will be presented by Dr. Mina Lobbous from the Cleveland Clinic.
Read more →INABIN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
IN8bio, a clinical-stage biopharmaceutical company, has announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting, scheduled for December 7-10, 2024. The presentation will focus on INB-100, which involves a pilot study of donor-derived gamma-delta T cell infusion following haploidentical hematopoietic stem-cell transplantation. Joseph McGuirk from The University of Kansas Cancer Center will be the presenter. This event highlights IN8bio's commitment to developing innovative therapies for cancer patients.
Read more →INABIN8bio Announces Pricing of $12.4 Million Private Placement
IN8bio, Inc. announced a definitive agreement for a private placement expected to generate approximately $12.4 million in gross proceeds. The funds will support the company’s operating plan into 2026 and aid in the clinical development of INB-100, a therapy for Acute Myeloid Leukemia. The placement is led by existing investors and comes as the company aims to enhance patient enrollment in a key trial. The closing of this placement, subject to customary conditions, is anticipated around October 4, 2024.
Read more →INABIN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
IN8bio, Inc. has prioritized its clinical pipeline by focusing on INB-100 for acute myeloid leukemia (AML), where the ongoing trial shows a promising 100% progression-free survival rate. The company has suspended enrollment in the INB-400 trial for glioblastoma as it seeks partnership opportunities, while also reducing its workforce by 49% to manage costs. Continued enrollment in the INB-100 trial aims to further de-risk the pathway to registration, with positive clinical data expected in future assessments.
Read more →INABIN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia - Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is activel
IN8bio has announced a strategic plan prioritizing its resources towards the development of INB-100 for acute myeloid leukemia (AML) due to promising clinical data. The company will undergo a workforce reduction of about 49% as part of this strategy. In parallel, IN8bio will halt its glioblastoma development program while continuing to monitor other ongoing trials. The decision comes after a Type B meeting with the FDA, where guidance was received to advance INB-100 as a post-transplant maintenance therapy, aiming for enhanced patient outcomes.
Read more →INABIN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
IN8bio, Inc. announced that CEO William Ho will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. The company is focused on gamma-delta T cell-based therapies for cancer, with its lead program INB-400 in Phase 2 trials for glioblastoma (GBM). This presentation aligns with IN8bio's effort to enhance investor awareness of its ongoing clinical trials and innovative treatment approaches in the biopharmaceutical sector.
Read more →INABIN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 Received FDA
IN8bio announced promising updates from their Phase 1 trials for INB-100 and INB-200, focusing on gamma-delta T cell therapies for oncology. All treated AML patients with INB-100 have achieved complete remission, and the trials indicate better than expected progression-free survival rates. The company has also received FDA guidance for moving forward with a registrational trial for INB-100. Overall, the clinical results support the advancement of these therapies into Phase 2 trials, showcasing the potential of gamma-delta T cells in cancer treatment.
Read more →INABIN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio, Inc. reported its second-quarter 2024 financial results, showcasing significant progress in their gamma-delta T cell therapies. Positive Phase 1 data revealed a 100% one-year complete remission rate among patients with hematologic malignancies, while a notable 92% of glioblastoma patients using INB-200 exceeded the median progression-free survival compared to standard treatments. The company is advancing its proprietary DeltEx platform, although it faces increased net losses and reduced cash reserves.
Read more →INABv3 IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies in
IN8bio reported strong Phase 1 clinical trial results with its gamma-delta T cell therapies, demonstrating 100% complete remission in hematologic malignancies and promising data in glioblastoma patients. The company continues to advance its innovative therapies, highlighted by a strong safety profile and the potential to revolutionize treatment for challenging cancer types. However, IN8bio also reported a net loss and reduced cash reserves, raising concerns about its financial stability as it continues clinical trials.
Read more →INABIN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
IN8bio, Inc. announced that CEO William Ho will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024. The company specializes in gamma-delta T cell therapies, aiming to develop treatments for solid and liquid tumors. Their current clinical trials include a Phase 2 trial of INB-400 for GBM and two Phase 1 trials for various hematologic malignancies. This conference presentation could enhance the company's visibility in the biopharmaceutical field.
Read more →INABIN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR)
IN8bio, Inc. presented encouraging findings from its Phase 1 trial of INB-100, showing that 100% of evaluable leukemia patients achieved a durable complete remission at the one-year mark. The study highlighted the therapy's potential to prevent relapse in high-risk patients undergoing hematopoietic stem cell transplantation, with the first three high-risk patients remaining alive and progression-free. The trial has been expanded to include more patients at a higher dose, with future updates expected by late 2024 and early 2025.
Read more →INABIN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting 92% of evaluable patients treated with INB-200 for glioblastoma exceeded a media
IN8bio presented promising preliminary results from its Phase 1 study of INB-200 for glioblastoma at the 2024 ASCO Annual Meeting. Notably, 92% of evaluable patients exceeded a median progression-free survival (PFS) of seven months, which is significantly higher than standard treatments. One patient has remarkably remained progression-free for nearly three years. The study demonstrated a favorable safety profile, with no serious toxicities reported across the dosing cohorts.
Read more →INABIN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
IN8bio, Inc. announced its participation at the International Society for Cell & Gene Therapy 2024, highlighting multiple presentations focused on their gamma-delta T cell therapies. COO Dr. Kate Rochlin emphasized the significance of their proprietary manufacturing platform in enhancing cancer treatment efficacy. The company is advancing its lead program, INB-400, into Phase 2 trials, targeting glioblastoma multiforme, while also working on other investigational candidates. The press release also contains forward-looking statements regarding anticipated outcomes from their therapies, with explicit acknowledgment of the inherent risks involved in clinical development.
Read more →INABIN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
IN8bio, Inc. announced that it will present updated results from its Phase 1 study of INB-200 for glioblastoma multiforme at the upcoming 2024 ASCO Annual Meeting. The therapy is designed for patients with newly diagnosed GBM and has shown early encouraging results, exceeding the expected median progression-free survival with standard treatment. Although no significant adverse effects were reported, the long-term efficacy of the therapy is still being evaluated. The upcoming presentation will further clarify the therapy's potential as a first-line treatment option.
Read more →INABIN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
IN8bio, Inc. has announced a presentation at the European Hematology Association 2024 Congress, scheduled for June 13-16 in Madrid, Spain. The presentation will detail updated interim results from their Phase 1 trial of gamma-delta T cell therapy INB-100, particularly after haploidentical stem cell transplantation for leukemia patients. Dr. Trishna Goswami emphasized the potential of the therapy to improve survival rates and reduce cancer recurrence without severe side effects. Further details of the presentation will be shared at the congress.
Read more →INABIN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio presented at the ASGCT 2024 Annual Meeting details of its proprietary gamma-delta T cell therapy manufacturing process, highlighting its robustness and reproducibility across various donor populations. The data revealed significant upregulation of key markers associated with potency and immune cell activity. Furthermore, the study showed consistent gene expression profiles between products sourced from healthy donors and glioblastoma patients. IN8bio's advancements in manufacturing indicate a promising step forward for their clinical programs targeting cancer therapies.
Read more →INABIN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio, Inc. reported its financial results for the first quarter of 2024, highlighting significant advancements in its gamma-delta T cell programs. The company presented promising preclinical data for its non-signaling Chimeric Antigen Receptor (nsCAR) platform that effectively targets cancer while preserving healthy tissue. IN8bio also announced the dosing of the first patient in the Phase 2 trial of INB-400 for glioblastoma multiforme and a recent publication detailing its innovative DeltEx Drug Resistant Immunotherapy. However, the company recorded an increased net loss and a diminished cash position compared to the previous year.
Read more →INABv3 IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effec
IN8bio reported its first quarter financial results for 2024, showcasing progress in its gamma-delta T cell programs, including a new preclinical data on its non-signaling Chimeric Antigen Receptor (nsCAR) platform. The company announced the dosing of the first patient in the Phase 2 autologous arm for glioblastoma multiforme and highlighted a peer-reviewed publication on its DeltEx immunotherapy. However, the report disclosed a net loss of $8.6 million, alongside a notable decrease in cash reserves from the previous quarter.
Read more →INABIN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio has successfully dosed its first patient in a Phase 2 clinical trial evaluating INB-400 for newly diagnosed glioblastoma at the Cleveland Clinic. This trial aims to assess the safety and effectiveness of INB-400 in combination with standard chemotherapy. Given the high relapse rate in glioblastoma patients, this advancement represents a significant opportunity for improved treatment options. INB-400 is distinguished by its resistance to chemotherapy, potentially enhancing immune response against the cancer.
Read more →INABIN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
IN8bio, Inc. announced it will present an oral session at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. The presentation, titled 'Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression', is scheduled for May 10, 2024. This highlights the company's focus on developing gamma-delta T cell therapies for cancer treatment, particularly its lead program, INB-400, currently in Phase 2 trials. The meeting will take place both in-person in Baltimore and virtually.
Read more →INABIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio, Inc. has announced that CEO William Ho will present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18th, 2024. The presentation will include a Q&A session and is aimed at engaging with potential investors. IN8bio is focused on developing gamma-delta T cell therapies for cancer and is currently advancing its lead program, INB-400, through clinical trials. Interested attendees can register for the conference and access the presentation afterward online.
Read more →INABIN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio, Inc. announced new preclinical data for its gamma-delta non-signaling CAR-T (nsCAR) therapy platform at the AACR Annual Meeting 2024. The findings demonstrate that the nsCAR constructs can selectively target leukemia cells while preserving healthy tissue, suggesting the potential for a broader therapeutic window. The data indicates a significant enhancement in tumor killing capabilities compared to traditional CAR therapies, and IN8bio is advancing further optimizations. This platform aims to increase treatment efficacy and safety against both hematologic and solid tumors.
Read more →INABIN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights • Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in
IN8bio, a clinical-stage biopharmaceutical company, reported significant achievements in its fourth quarter and full-year 2023 financial results. The company showcased unprecedented durability in remission for allogeneic cellular therapy INB-100 in leukemia, with 100% of evaluable patients remaining in remission. Additionally, positive results for INB-200 in newly diagnosed glioblastoma were presented, indicating longer-than-expected progression-free survival. Financially, IN8bio secured $14.4 million through a private placement that extends its operational runway into the first quarter of 2025.
Read more →INABIN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio has announced the presentation of promising new preclinical data for its novel non-signaling gamma-delta CAR-T platform, INB-300, at the upcoming AACR Annual Meeting 2024. This innovative technology aims to selectively target cancer cells expressing specific antigens, similar to CD-33 and CD-123, while sparing healthy tissues. By leveraging the innate immune recognition of gamma-delta T cells, IN8bio seeks to improve outcomes for patients with various cancers that traditional CAR-T therapies struggle to treat effectively. The company is optimistic about further developing its pipeline and addressing significant unmet needs in cancer treatments.
Read more →INABIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
IN8bio, Inc. announced a publication in Frontiers in Immunology detailing its novel gamma-delta T cell therapy for the treatment of glioblastoma (GBM), an aggressive brain cancer. The therapy, known as DeltEx Drug Resistance Immunotherapy, is designed to enhance patient survival and quality of life by combining genetically engineered T cells with standard chemotherapy. Early trial results suggest the therapy is manageable and may improve progression-free survival rates compared to traditional treatments. IN8bio is currently conducting several trials to further assess the safety and efficacy of its therapeutic approach for GBM and other solid tumors.
Read more →INABIN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
IN8bio, Inc. has highlighted its recent achievements and outlined its objectives for 2024. At major medical meetings, the company presented positive results, including durable complete remissions in all evaluable leukemia patients in a Phase 1 trial of INB-100 and extended progression-free survival in glioblastoma patients treated with INB-200. IN8bio has also initiated a Phase 2 trial for INB-400 and appointed Dr. Corinne Epperly to its Board of Directors. Furthermore, a recent private placement has bolstered the company's financial position, extending its cash runway into 2025.
Read more →INABIN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
IN8bio announced a positive clinical update regarding its Phase 1 trial of INB-100, where 100% of evaluable patients with leukemia achieved durable complete remission. All participants are alive and relapse-free, with some remaining so for over three years. The trial data highlighted significant in-vivo expansion of gamma-delta T cells, indicating the therapy's potential curative impact. The company plans to expand the trial further with additional patient enrollments and present updated data at future medical conferences.
Read more →INABIN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 mi
IN8bio has announced a pricing of up to $46.9 million in a private placement to support its operations and clinical development. The initial closing will yield $14.4 million, helping extend the company's cash runway into 2025. The funds will be used for advancing their gamma-delta T cell therapies, with potential additional capital available through exercised warrants. The private placement is expected to close on December 13, 2023, pending customary conditions.
Read more →INABIN8bio Appoints Dr. Corinne Epperly to Board of Directors
IN8bio, Inc. has appointed Dr. Corinne Epperly to its Board of Directors, recognizing her extensive background in immuno-oncology and cell therapies. With over 20 years of experience across leading organizations, Dr. Epperly will contribute her insights to IN8bio’s strategic and operational efforts. She will also serve on the Compensation Committee and Science & Technology Committee. Her expertise is seen as crucial in advancing IN8bio's innovative gamma-delta T cell therapies for cancer treatment.
Read more →INABIN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
IN8bio is set to host a conference call on December 12, 2023, to discuss updated clinical data from its Phase 1 trial of INB-100. The presentation will follow a poster session at the ASH 65th Annual Meeting on December 11, where the treatment's potential in hematologic malignancies will be highlighted by clinical expert Dr. Michael Bishop. The INB-100 trial explores the use of donor-derived allogeneic gamma-delta T cells to improve outcomes for patients following hematopoietic stem cell transplantation.
Read more →INABIN8bio s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survi
IN8bio has reported promising results from its INB-200 trial, which targets newly diagnosed glioblastoma patients. All participants who completed the mandated doses experienced progression-free survival exceeding seven months, with two patients still alive after more than two years. These findings were presented at the Society for Neuro-Oncology Annual Meeting and indicate potential improvements over standard treatments. The trial's continued enrollment and follow-up are expected to provide further insights into the efficacy of this innovative therapy.
Read more →INABIN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
IN8bio, a clinical-stage biopharmaceutical company, will present clinical data on its innovative therapies INB-200 and INB-400 aimed at treating newly diagnosed glioblastoma multiforme at the SNO 28th Annual Meeting. The presentation includes a late-breaker poster detailing results from a Phase 1 trial for INB-200 and a poster on a Phase 2 trial of INB-400. Both therapies utilize genetically modified gamma-delta T cells and may provide new treatment options for patients with this aggressive form of brain cancer. Additionally, INB-400 has been granted Orphan Drug Designation by the FDA, marking significant recognition of its potential therapeutic benefits.
Read more →INABIN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update • Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hemat
IN8bio, a clinical-stage biopharmaceutical company, reported its third quarter 2023 financial results along with significant operational updates. Key developments include the completion of dose escalation in the Phase 1 trial of INB-100 and the initiation of enrollment for the Phase 2 trial of INB-400, both targeting glioblastoma. Positive clinical data have been shared at recent meetings, and upcoming presentations are scheduled for the ASH and SNO Annual Meetings. Despite a reported net loss and a decrease in cash reserves, the company remains optimistic about its innovative gamma-delta T cell therapies.
Read more →INABIN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
IN8bio presented new biologic correlative data from the Phase 1 trial of INB-200 at the SITC Annual Meeting, showcasing its potential in treating glioblastoma multiforme (GBM). The trial results indicate that single and repeat doses of this DeltEx drug-resistant immunotherapy can successfully induce T cell persistence and sustain an immune response. Additional patient survival and enrollment data will be discussed at the upcoming Society for Neuro-Oncology Annual Meeting. IN8bio aims to leverage its innovative T cell therapy approach to improve treatment outcomes for solid tumors, specifically GBM.
Read more →INABIN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
IN8bio presented positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the SITC Annual Meeting. The findings indicate effective production of iVd1+ gamma-delta T cells linked to low risk of cytokine release syndrome (CRS), with strong tumor-killing abilities against various cancers. The company's proprietary method promises scalable manufacturing suitable for therapeutic applications. Overall, this data supports IN8bio's continued development of innovative cancer treatments utilizing gamma-delta T cells.
Read more →INABIN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
IN8bio, Inc. has announced new positive findings from the Phase 1 trial of INB-100, focused on patients with hematologic malignancies. The data will be presented at the 2023 American Society of Hematology Annual Meeting. The treatment showcases promising efficacy, safety, and robust T cell expansion, while updated efficacy and durability results are expected at the upcoming conference. The trial has completed dose-escalation, with a total of ten patients treated thus far.
Read more →INABIN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
IN8bio, a clinical-stage biopharmaceutical company, will be represented by CEO William Ho at the Truist Securities BioPharma Symposium on November 8-9, 2023. The company anticipates sharing multiple preclinical and clinical updates before the end of the year at various upcoming medical conferences. Known for its gamma-delta T cell therapies, IN8bio is focused on treating solid and liquid tumors and is currently conducting Phase 2 and Phase 1 trials in glioblastoma and leukemia. The firm's ongoing innovations aim to address various cancer types.
Read more →INABIN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagn
IN8bio, Inc. has completed the dose escalation phase of its Phase 1 trial for INB-100, a gamma-delta T cell therapy for leukemia, showing promising results with all evaluable patients in complete remission. The company also announced the initiation of patient enrollment for its Phase 2 trial of INB-400, which targets newly diagnosed glioblastoma multiforme. This trial aims to provide more detailed insights into the efficacy and safety of their therapies, particularly in challenging cancer indications. The promising early results and newly activated sites mark significant progress in IN8bio's therapeutic developments.
Read more →INABIN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
IN8bio, Inc. announced two poster presentations at the Society for Immunotherapy of Cancer's 38th Annual Meeting, occurring from November 1-5, 2023, in San Diego, CA. The presentations will showcase positive findings from the ongoing Phase 1 trial of INB-200, aimed at treating newly diagnosed glioblastoma. Additionally, insights on manufacturing strategies for iPSC-based gamma-delta T cells will be highlighted. This marks a significant step in developing innovative therapies for solid tumors using genetically modified T cells.
Read more →INABIN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
IN8bio, a clinical-stage biopharmaceutical company, is set to host a Research & Development Day on October 12, 2023, in New York City. The event will feature insights on gamma-delta T cell therapies and presentations from notable oncology experts. Attendees will gain updates on IN8bio's clinical and scientific programs, including upcoming data releases at significant fall medical meetings. The company is currently conducting Phase 1 clinical trials alongside an imminent Phase 2 trial for its lead product candidates.
Read more →INABIN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
IN8bio, Inc. has announced that its CEO, William Ho, will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 27, 2023. The company's innovative focus on gamma-delta T cell therapies positions it as a significant player in the biopharmaceutical industry, particularly for treating tumors. IN8bio is currently involved in multiple Phase 1 and upcoming Phase 2 clinical trials, showcasing its commitment to advancing cancer treatments.
Read more →INABIN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
IN8bio has announced the granting of new global patents that enhance its intellectual property portfolio for the DeltEx Drug Resistant Immunotherapy (DRI) platform. These patents will allow the integration of IN8bio's DRI platform with Chimeric Antigen Receptor T-cell (CAR-T) therapy and checkpoint inhibitors, which could improve treatments for solid tumor cancers. With a total of 19 granted patents, the company aims to expand its applications in the fight against cancer. The CEO highlighted the importance of this robust IP foundation for the growth of IN8bio’s business in developing effective gamma-delta T cell therapies.
Read more →INABIN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
IN8bio, Inc. will have its CEO, William Ho, participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. The company focuses on developing gamma-delta T cell therapies for treating solid and liquid tumors. With two ongoing Phase 1 clinical trials for glioblastoma and leukemia, IN8bio is also set to initiate a Phase 2 trial for glioblastoma, reflecting its active development pipeline. The conference presentation will be accessible live and later on their website.
Read more →INABIN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
IN8bio, a clinical-stage biopharmaceutical company focusing on gamma-delta T cell therapies, announced that CEO William Ho will speak at the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17, 2023. The company is conducting two Phase 1 clinical trials for its treatments for glioblastoma and leukemia. Additionally, IN8bio plans to initiate a Phase 2 trial for glioblastoma treatment following recent IND clearance. This presentation highlights the company's commitment to advancing its innovative therapies in the oncology field.
Read more →INABIN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeti
IN8bio reported its financial results for the second quarter of 2023, highlighting significant advancements in its gamma-delta T cell programs. The company presented positive Phase 1 data from the INB-200 trial, demonstrating that all treated patients exceeded the median progression-free survival. Additionally, promising preclinical findings in ovarian cancer were shared, indicating the potential of DeltEx gamma-delta T cells. The INB-400 trial is set to begin enrollment for newly diagnosed glioblastoma patients later this year.
Read more →INABIN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
IN8bio, a clinical-stage biopharmaceutical company, has opened a new 10,000 square foot research and development facility in Birmingham, AL. This state-of-the-art center is designed to enhance its preclinical, clinical, and process development capabilities, particularly for its gamma-delta T cell therapies aimed at treating cancer. The company's CEO emphasized the significance of this expansion in supporting local scientific talent and the broader community. In addition to hosting a grand opening event, the facility will play a crucial role in advancing IN8bio's innovative pipeline of cancer therapies.
Read more →INABIN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting 100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients th
IN8bio has released a positive update on its Phase 1 clinical trial for INB-200, a treatment for glioblastoma, presented at the 2023 ASCO Annual Meeting. The data shows that all eight patients treated have surpassed the historical median progression-free survival rates. Notably, two patients are reported to be progression-free and without symptoms after their treatment regimen. The company plans to offer further updates as enrollment in the trial continues.
Read more →INABIN8bio s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target soli
IN8bio, Inc. has announced encouraging preclinical results demonstrating the efficacy of its DeltEx Gamma-Delta T cells in targeting and eliminating ovarian cancer cells, including those resistant to conventional treatments. The data were shared at the ASGCT Annual Meeting, indicating the synergy between gamma-delta T cells and chemotherapy. This combination could pave the way for novel therapeutic strategies for ovarian cancer patients. The company is optimistic about the broader implications of DeltEx technology and plans to evaluate its use in ovarian cancer further, alongside ongoing clinical trials for other indications.
Read more →INABIN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of eval
IN8bio has reported a strong first quarter of 2023, showcasing promising results from their INB-100 therapy, which led to complete remissions in all evaluated leukemia patients. The company has received FDA orphan drug designation for INB-400 and INB-410, broadening its potential treatment applications. Financially, IN8bio raised $9.9 million to strengthen its cash flow, although it also reported a net loss of $7.5 million for the period. Additional clinical updates are expected later in 2023.
Read more →INABIN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
IN8bio announced new preclinical data for INB-400 at the ASGCT Annual Meeting, indicating its potential as a novel therapy for ovarian cancer. This data shows that the gamma-delta T cell therapeutic can effectively target and kill various ovarian cancer cell lines, including high-grade serous ovarian cancer. The results suggest a synergistic effect when combined with chemotherapy, presenting hope for improved patient outcomes in an area with significant unmet medical needs. The company plans to further explore INB-400's applicability across a broader range of solid tumors.
Read more →INABIN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
IN8bio, Inc. has appointed Dr. Jeremy Graff to its Board of Directors, recognizing his extensive experience in oncology and drug development. Dr. Graff has a notable history at Eli Lilly where he led efforts on multiple clinical assets and currently serves as Chief Scientific Officer at IMV Inc. His leadership is expected to significantly contribute to the advancement of IN8bio's gamma-delta T cell therapies, which aim to address unmet needs in cancer treatment. The company is currently involved in several clinical trials targeting various cancer indications.
Read more →INABIN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
IN8bio, Inc. has announced that new Phase 1 study results for its INB-200 treatment for glioblastoma will be presented at the 2023 ASCO Annual Meeting. The oral presentation aims to discuss the safety, tolerability, and efficacy of this investigational therapy in patients with newly diagnosed GBM, a highly aggressive brain cancer with limited treatments available. This presentation underscores the potential of INB-200 in improving patient outcomes through innovative T cell therapy.
Read more →INABIN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
IN8bio has received FDA orphan drug designation for its genetically engineered gamma-delta T cell therapies, INB-400 and INB-410, focused on the treatment of newly diagnosed glioblastoma multiforme (GBM). This designation grants potential 7-year market exclusivity and signifies the company as a leader in innovative cancer therapies. Patient enrollment for a Phase 2 clinical trial of INB-400 is expected to begin in the second half of 2023. The company's advancements aim to improve treatment options for a cancer type that has seen little progression over the past years.
Read more →INABIN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 INB-100 treatment has achieved durable 100% co
IN8bio presented new data at the EBMT 2023 conference revealing that INB-100 led to durable complete remissions in all evaluable leukemia patients. The treatment demonstrated a significant increase in gamma-delta T cell levels, which correlated with improved patient outcomes. All patients treated thus far have remained alive and progression-free, including some for over three years. The company is expanding the trial at a promising Dose Level 2, with further data expected later this year.
Read more →INABIN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the a
IN8bio has announced promising preclinical data for its novel non-signaling CAR (nsCAR) platform, particularly highlighting the INB-330 program targeting CD33 in acute myeloid leukemia (AML). The results suggest that the nsCAR technology can effectively distinguish between leukemic and healthy cells, potentially reducing side effects associated with previous therapies. The company aims to further develop this technology and work on additional targets to enhance treatment options for challenging cancers. Data presented at the AACR Annual Meeting 2023 supports ongoing evaluations of these innovative therapies.
Read more →INABIN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
IN8bio, Inc. is set to present positive new data from its ongoing Phase 1 trial of INB-100 at the EBMT 2023 Annual Meeting in Paris. The data, updating on durability of responses and developing complete remissions in leukemia patients, demonstrated that four patients remained in durable complete remission with no dose-limiting toxicities observed. The findings include robust immune reconstitution through the first 100 days post-treatment. The presentation is scheduled for April 23, 2023, and reflects promising advancements in gamma-delta T cell therapies.
Read more →INABIN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update • All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and
IN8bio announced positive clinical results and financial outcomes for Q4 and full-year 2022. The company reported that all Cohort 1 leukemia patients in a Phase 1 trial of INB-100 have maintained remission for over 18 months. INB-200 and INB-300 are also exhibiting promising results, with updates expected in upcoming medical meetings. On the financial front, however, IN8bio experienced a net loss of $28.5 million, reflecting increased R&D investment.
Read more →INABIN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
IN8bio, Inc. announced the presentation of preclinical data for its gamma-delta CAR-T technology, INB-300, at the AACR Annual Meeting 2023. The data showed that INB-300 can effectively distinguish between malignant and healthy cells, suggesting its potential for treating previously 'undruggable' tumors. While the company is not moving this construct into clinical advancement, the results are encouraging, particularly against the CD19 target, demonstrating an 80% efficacy against leukemic cells. IN8bio plans to explore additional targets for future studies.
Read more →INABIN8bio to Present at the Cowen 43rd Annual Healthcare Conference
IN8bio, a clinical-stage biopharmaceutical company, announced that its CEO William Ho will present an overview of the company at the Cowen 43rd Annual Healthcare Conference on March 7, 2023. The presentation highlights IN8bio's focus on developing gamma-delta T cell therapies for treating solid and liquid tumors. Currently, the company is conducting two Phase 1 clinical trials for its lead product candidates and is set to initiate a Phase 2 clinical trial for glioblastoma. This event signifies IN8bio's ongoing commitment to advancements in cancer treatment.
Read more →INABIN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Grea
IN8bio has presented promising preclinical data on its non-signaling CAR-T platform, which effectively targets cancer cells while preserving healthy tissue. This innovative approach utilizes gamma-delta T cells, allowing for a safer and more effective treatment of conditions like acute myeloid leukemia and solid tumors. The findings suggest a significant increase in cytotoxicity, with the platform showing over a 15x greater efficacy against leukemic cells compared to healthy B cells. The data paves the way for further development and potential clinical applications of this technology in oncology.
Read more →INABIN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023. The company specializes in gamma-delta T cell therapies for treating solid and liquid tumors. IN8bio is currently running two Phase 1 clinical trials for its product candidates INB-200 and INB-100, while also preparing to initiate a Phase 2 trial for INB-400. These endeavors highlight the company's focus on innovative cancer treatments.
Read more →INABIN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference
IN8bio, a clinical-stage biopharmaceutical company, announced that its CEO, William Ho, will present at the B. Riley Securities' 3rd Annual Virtual Oncology Conference on January 18, 2023. The company focuses on developing gamma-delta T cell therapies for both solid and liquid tumors. Currently, IN8bio is conducting Phase 1 clinical trials for its leading product candidates targeting glioblastoma and leukemia, and is set to initiate a Phase 2 trial for glioblastoma. Additionally, IN8bio is exploring various preclinical programs to address other solid tumor types.
Read more →INABIN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.
IN8bio, Inc. has provided an optimistic clinical update regarding INB-200, a treatment for newly diagnosed glioblastoma, reporting over the median progression-free survival among participants. The CEO highlighted the positive response durability and a favorable safety profile as promising indicators for their ongoing Phase 1 trial. Additionally, IN8bio outlined its ambitious goals for 2023, which include launching a Phase 2 study for another treatment candidate and broadening its focus to additional tumor types.
Read more →INABIN8bio to Present at Biotech Showcase 2023 in San Francisco
IN8bio, a clinical-stage biopharmaceutical company, announced that its CEO, William Ho, will present at the Biotech Showcase 2023 in San Francisco from January 9-11, 2023. The presentation will focus on their innovative gamma-delta T cell therapies aimed at treating solid and liquid tumors. IN8bio is also participating in the 41st Annual J.P. Morgan Healthcare Conference, which will allow management to meet with potential investors. The company is actively involved in clinical trials for its lead products, INB-200 and INB-100, as well as initiating INB-400 following recent IND clearance.
Read more →INABIN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 Results from the first cohort of patients with hematological malignancies
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 NEW YORK, December 12, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-de
Read more →INABIN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss recent cli
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma NEW YORK, December 8, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today anno
Read more →INABIN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia;
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress NEW YORK, Nov. 10, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx
Read more →INABIN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update • INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia;
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update -INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meetin
Read more →INABIN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. Partnered with the Dunbar CAR T-Cell Program at the University of Louisville as t
Read more →INABIN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive
Read more →INABIN8bio to Present at November Investor Conferences
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be present
Read more →INABIN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bio’s Chief Executive Offi
Read more →INABIN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400
Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studies Potential to expand the agreement to support commercial-scale manufacturing NEW YORK and LOUISVILLE, Ky, Sept. 15, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq:
Read more →INABIN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, IN8bio’s Chief Executive Officer w
Read more →INABIN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.
Read more →INABIN8bio to Present at September Investor and Scientific Conferences
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced the presentations it will be making at investor
Read more →INABIN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering NEW YORK, Aug. 19, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utili
Read more →INABIN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the closing of its previously ann
Read more →INABIN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update • Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the AS
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update -Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting. -Presented data from Phase 1 clinical trial of
Read more →INABIN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of NEW YORK, August 11, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx
Read more →INABIN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients All three patients from the first cohort of hig
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients NEW YORK, July 27, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on
Read more →INABIN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive t
Read more →INABIN8bio to Present at July Investor and Scientific Conferences
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations: O
Read more →INABIN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, announced that William Ho, CEO will be presenting
Read more →INABIN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall survival (OS). An unmethylated GBM patient remains stable at one-year post enrollment. Patient received three-repeated dos
Read more →INABIN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs). Yesterday, at the American Society for Gene & Cell Therapy (ASGCT) 25th Annual Meeting, IN8bio announced data on its iPSC platform showing
Read more →INABIN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update • Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients cont
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update -Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data. -INB-100 patient update at Euro
Read more →INABIN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced the Company’s new induced pluripotent stem cell (iPSC) based gamma-delta T
Read more →INABIN8bio to Present at May Investor and Scientific Conferences
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced May conference presentations: ISC
Read more →INABIN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments
Urvashi Patel, Ph.D., as Vice President, Regulatory Affairs Stacey Bilinski, as Vice President, Clinical Operations NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of i
Read more →INABIN8bio to Present at April Investor and Scientific Conferences
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced April conference presentations:
Read more →INABIN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant All three patients with high-risk or
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant NEW YORK, March 28, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical compa
Read more →INABIN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update • All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), hav
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update -All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), have shown a well-tolerated safety profile and longer than anticipated
Read more →INABIN8bio to present at March Investor and Scientific Conferences
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations: European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress
Read more →INABIN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events: BIO CEO & Investor Conference, February 14 - 17, 2
Read more →INABIN8bio to Present at Upcoming January Investor Conferences
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive
Read more →INABIN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort Cohort 1 dosing is complete with three patients who received a single dose of INB-200 with no dose limiting toxicities (DLTs), cytok
Read more →INABIN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant The ongoing Phase 1 trial of INB-100 is the f
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant NEW YORK, Dec. 16, 2021 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focuse
Read more →INABIN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate
Read more →INABIN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the appointment of Trishna Goswam
Read more →INABIN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its proprietary DeltEx platform, today announced a poster presentation
Read more →INABIN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update  Closed initial public offering raising net proceeds after expenses of $32.3 million.  Added two new independent Directors
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update Closed initial public offering raising net proceeds after expenses of $32.3 million. Added two new independent Directors and increased diversity across our Board of Directors. Completed patient d
Read more →INABIN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific
Read more →INABIN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma MGMT-modified gamma-delta T cells are engineered to survive chemotherapy and form the basis of IN8bio’s Drug Res
Read more →INABIN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021
NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive
Read more →INABIN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update  First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100  Data presentations made at ASCO and AAC
IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100 Data presentations made at ASCO and AACR $40M initial public offering (IPO) in August 2021 to fund continuing oper
Read more →INABIN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, President, Chief
Read more →INABIN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
The first cohort has completed dosing with IN8bio’s donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) observed to date The first two patients continue to be in complete remission m
Read more →INABIN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and
Read more →INABIN8bio Announces Pricing of Initial Public Offering
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies utilizing its DeltEx platform (“IN8bio” or the “Company”), today announc
Read more →INABIN8bio Launches Proposed Initial Public Offering
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma delta T-cell therapies utilizing its DeltEx platform, today announced that it has launched
Read more →INABIN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme
Single-dose administration of IN8bio’s genetically modified gamma delta T-cells in lymphodepleted glioblastoma multiforme (GBM) patients was well tolerated No observed dose limiting toxicities (DLTs) such as infusion reactions, cytokine release syndrome (CRS), or neurotoxicity
Read more →INABIN8bio Presents First Cohort Phase 1 Clinical Data on INB-200 at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
NEW YORK, May 20, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies, announced today that topline data from the first cohort of the on-g
Read more →INABIN8bio to Participate in Upcoming May Scientific Conferences
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, announced that the Company’s co-founder a
Read more →INABIN8bio Demonstrates In Vitro Activity of DeltEx DRI CAR-T Cells Against Glioblastoma Multiforme at AACR
DeltEx DRI CAR-T cells are gamma-delta T cells engineered with a Chlorotoxin CAR-T binding domain and a chemotherapy resistance gene, which enhances binding to tumor cells and survival of concomitant dosing with alkylating chemotherapies, such as temazolomide, or TMZ. NEW YORK,
Read more →INABIN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or the “Company”), a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies, announced a presentation on the scientific rationale and clinical basis for the use of gamm
Read more →INABIN8bio Appoints Patrick McCall as Chief Financial Officer
NEW YORK, Feb. 08, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced
Read more →INABIN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product candidate, at ASH 2020
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced
Read more →INABIN8bio to Present at Upcoming December Investor Conferences
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced
Read more →INABIN8bio Appoints Alan S. Roemer as Chairman
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced
Read more →INABIN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells, tod
Read more →Competitive Position
How INAB ranks across every disease it competes inCompetitive Position is a premium feature
See how INAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial